Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

[1]  He Huang,et al.  Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study , 2022, Cell Research.

[2]  J. Klco,et al.  Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies , 2022, Blood.

[3]  G. Lucchini,et al.  CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy , 2022, Blood advances.

[4]  Jason M. Gehrke,et al.  Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL , 2022, Blood.

[5]  Hui Wang,et al.  Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial. , 2022, Blood.

[6]  Zhaoming Li,et al.  Autologous nanobody-derived fratricide-resistant CD7-CAR T cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Ying Yuan,et al.  Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Delphine Potier,et al.  Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy , 2021, Nature Communications.

[9]  M. Toribio,et al.  Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia , 2020, International journal of molecular sciences.

[10]  R. Fanin,et al.  Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study , 2020, American journal of hematology.

[11]  D. Teachey,et al.  Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  C. Pui,et al.  Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. , 2019, The Lancet. Oncology.

[13]  J. Schachter,et al.  Early and late hematologic toxicity following CD19 CAR-T cells , 2019, Bone Marrow Transplantation.

[14]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Hans Bitter,et al.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia , 2018, Nature Medicine.

[16]  Ciaran M. Lee,et al.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. , 2017, Blood.

[17]  M. Konopleva,et al.  The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience , 2014, Leukemia.

[18]  E. Shpall,et al.  Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[20]  M. Labopin,et al.  Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT , 2012, Leukemia.

[21]  M. Tormo,et al.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.

[22]  A. Ferrando,et al.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). , 2009, Blood.

[23]  H. Dombret,et al.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.

[24]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[25]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[26]  Terry L. Smith,et al.  Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.

[27]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.